2016 Q2 inventory of 20 gene listed companies financial report

Recently, 20 gene listed companies released the second quarter 2016 financial report. Let's take a look at it. PS: Every gene editing/treatment company has a giant “dad” behind it.

2016 Q2 inventory of 20 gene listed companies financial report

1 - Gene Sequencer

2016 Q2 inventory of 20 gene listed companies financial report

In the second quarter of 2016, Illumina's revenue was $600 million, an increase of 11% year-on-year, with a gross margin of 70.6% and a net profit attributable to shareholders of $120 million ($0.82 per share). R&D investment in the quarter was US$124.6 million, accounting for 19% of total revenue, compared with US$96.2 million in R&D expenses in the second quarter of 2015 (15.8% of total revenue), an increase of 29.5%.

2016 Q2 inventory of 20 gene listed companies financial report

Benefiting from the strong market demand in China, South Korea and India, in 2016 Q2, Thermo's revenue was $4.554 billion, up 6% year-on-year. Operating profit was $638 million, an increase of 7% compared to $596 million in Q2 in 2015. In 2016, Q2 R&D investment was US$182 million, accounting for 4% of total revenue. The quarterly net profit was $517 million. In the life sciences segment, revenues rose 13% to $1.28 billion, and operating margins were as high as 28.9%. During the quarter, Thermo acquired the electron microscope company FEI for $4.2 billion.

2016 Q2 inventory of 20 gene listed companies financial report

Pacific Biosciences, a producer of third-generation gene sequencers, reported revenue of $20.7 million in 2016, down 17% year-on-year. Product and service revenues were $17.1 million, a 51% increase from the $11.3 million in Q2 in 2015. R&D investment was US$175 million, accounting for 84.5% of total revenue. The company's overall gross profit was US$10.6 million, with a gross margin of 51.3% and a net loss of US$18.5 million in the second quarter.

2 - genetic testing

2016 Q2 inventory of 20 gene listed companies financial report

In vitro cancer detection and diagnosis company Foundation Medicine's Q2 revenue for 2016 was US$28.24 million, up 25.7% year-on-year; R&D investment was US$18.5 million, accounting for 65.5% of revenue, compared with R&D investment of US$10.256 million in the same period of 2015, up 80.4% year-on-year. %. The net loss for the quarter was $289.94 million. Foundation Medicine has received support from Bill Gates, Google Ventures and many others.

2016 Q2 inventory of 20 gene listed companies financial report

Natera is one of the four largest non-invasive prenatal genetic testing (NIPT) companies in the United States. In Q2 2016, Natera's total detection volume reached 100,000 cases, a year-on-year increase of 49%. Among them, the number of NIPT detections was 80,000, a year-on-year increase of 38%. Benefiting from high-speed growth in inspections, Q2 revenue was $52 million, up 15% year-on-year; gross profit was $21 million, gross margin was 40%; R&D investment was $10.3 million (19.8% of total revenue), up 53% year-on-year %. 2016 Q2 net loss increased by 15% year-on-year to US$23.2 million.

2016 Q2 inventory of 20 gene listed companies financial report

As one of the major NIPT service providers in the United States, Sequenom's second quarter 2016 revenue was $29.3 million, a year-on-year decrease of 10.7%. The NIPT has a detection volume of 41,400 (including MaterniT21 Plus, MaterniT Genome, and VisibiliT). R&D investment in the quarter fell 28% year-on-year to US$4.1 million, accounting for 14% of total revenue; quarterly net loss was US$6.3 million.

Curing Box

Curing Box,Uv Curing Box,Light Curing Box,Uv Light Curing Box,Curing Chamber

Rolence Enterprise Inc. , https://www.rolencedent.com